Insights in Gynecologic Oncology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Opinion   
  • Current Trends Gynecol Oncol 2022, Vol 7(1): 109
  • DOI: 10.4172/ctgo.1000109

Cabozantinib is a New Sarcoma Therapy

Gelderblom, Hans*
Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands
*Corresponding Author : Gelderblom, Hans, Hans Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands, Email: gelderblomhans@gmail.com

Received Date: Jan 21, 2022 / Published Date: Feb 18, 2022

Citation: Hans G (2022) Cabozantinib is a New Sarcoma Therapy. Current Trends Gynecol Oncol, 7: 109. Doi: 10.4172/ctgo.1000109

Copyright: © 2022 Hans G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top